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In order for the pharmacological action of a topical dermal drug product to occur, the drug must first be 
released from the vehicle to be available to penetrate the skin layers and reach the site of action. Drug 
release is mainly dependent on the characteristics of the formulation. Currently, to register a generic 
or a similar drug product in Brazil performance testing of topical drug products for local action is not 
required. In this context, this aim of this study was to evaluate the in vitro release of commercial diclofenac 
diethylamine gel products available on the Brazilian pharmaceutical market, using the vertical diffusion 
cell method. Factors which may influence the test, such as the type of membrane used, and the effect 
of the formulation characteristics on the diffusion rate were evaluated. Brazilian legislation currently 
allows generic drug products to contain excipients other than the reference drug, which may affect the 
drug release from the vehicle. Only one of the four generic drug products tested could be considered 
equivalent to the reference Cataflam Emulgel®. The cellulose acetate and polyethersulfone membranes 
tested were found to be interchangeable in the in vitro release studies carried out on this product.
Uniterms: In vitro release test. Diclofenac diethylamine/gel. Synthetic membranes. Generic semisolid 
drug products.
Para exercer ação farmacológica, medicamentos tópicos de aplicação cutânea precisam, primeiramente, 
liberar o fármaco do veículo, para que desta forma ele se torne disponível para penetração nas camadas 
da pele, até atingir seu local de ação. A liberação do fármaco do veículo depende principalmente das 
características da formulação. Até a presente data, para registrar um medicamento genérico ou similar no 
Brasil não se exigem testes de desempenho para produtos tópicos de ação local. O presente trabalho teve 
como objetivo avaliar a liberação in vitro de especialidades farmacêuticas de diclofenaco dietilamônio gel 
do mercado farmacêutico brasileiro, usando o sistema de célula de difusão vertical. Avaliaram-se fatores 
que influenciam o teste como o tipo de membrana usada nos ensaios de liberação e características da 
formulação que impactam a velocidade de difusão. A legislação vigente no País permite que medicamentos 
genéricos contenham excipientes diferentes do medicamento referência. Esta diferença afetou a liberação 
do fármaco do veículo. Dos quatro medicamentos genéricos testados apenas um seria considerado 
equivalente ao medicamento referência Cataflam Emulgel®. As membranas de acetato de celulose e 
polietersulfona testadas apresentaram-se intercambiáveis nos estudos de liberação desse produto.
Unitermos: Teste de liberação in vitro. Diclofenaco dietilamônio/gel. Membranas sintéticas. 
Medicamentos genéricos semissólidos.
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INTRODUCTION
In vitro performance tests for solids, such as 
dissolution tests, have been extensively used as a tool in 
the development of drug formulations, in quality control 
procedures to ensure lot-to-lot uniformity, to monitor 
changes in the process and formula and to predict the in 
vivo performance of the product. A new test to evaluate 
the performance of semisolid products with the same aims 
as the dissolution test has been the subject of extensive 
discussion (Shah, 2005).
Currently, the performance testing system employing 
the vertical diffusion cell (VDC) is commonly applied to 
semisolid products, specifically creams, ointments and 
gels, and also to lotions. This procedure quantifies the 
release of the active component from the formulation, 
which diffuses through a membrane into a receptor 
solution (Ueda et al., 2009).
Generic drugs in semisolid form are launched in 
large numbers annually onto the Brazilian market and, 
as yet, there is no specific legislation regulating the 
performance testing of these products. In Brazil, the 
current legislation for the registration of generic and 
similar topical skin products without systemic absorption 
allows that bioequivalence is replaced by pharmaceutical 
equivalence, provided that the drug concentration is 
the same as the reference and excipients with the same 
function are present in compatible concentrations (Brasil, 
2003).
In 2009, the United States Pharmacopeia Forum 
suggested the use of VDCs with synthetic membranes to 
test the performance of topical products (Ueda et al., 2009). 
In the same year, with the publication of the RDC n. 48, 
ANVISA (the regulatory agency in Brazil), the Brazilian 
government required that an in vitro permeation study 
be carried out to compare semisolid formulations before 
and after post-approval changes (Brasil, 2009). However, 
the products are not compared with the reference drug at 
the time of registration. Despite this requirement, there 
is no official guidance for the Brazilian pharmaceutical 
industry regarding how to perform the test or providing 
specifications.
The aim of this study was to evaluate the situation 
regarding semisolid pharmaceutical forms of generic drugs 
available on the Brazilian market. In addition, since there 
is no standardization of the test parameters, such as the 
type of artificial membrane to be used, the development 
of release test methodologies is also discussed based on 
formulations of diclofenac diethylamine (DDA) gel, a 
widely used anti-inflammatory topical drug, studied as a 
model formula/drug.
MATERIAL AND METHODS
Products
The topical dermatological dosage forms were 
purchased on the Brazilian market, these being the 
reference Cataflam Emulgel® 11.6 mg/g (manufactured by 
Novartis Pharma Produktions GmbH, Germany, imported 
by Novartis Biociências S.A., Brazil) and four generic 
drug products produced by different manufacturers and 
referred to herein as generic A, generic B, generic C and 
generic D.
Reagents
Two types of hydrophilic synthetic membranes, with 
0.45 µm pore size, were used in this study: polyethersulfone 
(47 mm diameter, thickness ≥130 and ≤155 µm, Millipore®, 
USA) and cellulose acetate (47 mm diameter, 120 µm 
thickness, Sartorius®, Germany). Reagents included a 
diclofenac sodium standard (99.08%). All other reagents 
were of analytical grade and used as received.
In vitro release test
The in vitro release tests were performed using six 
vertical diffusion cells (Permegear®) per formulation. The 
diffusional area of the cell was 1.75 cm2 and the receptor 
compartment had a capacity of approximately 10.5 mL. 
The membranes were cut to a diameter of 25 mm and 
saturated for 30 minutes in receptor medium (phosphate 
buffer pH 7.4) before starting the experiment. The cell was 
filled with degassed receptor medium and the membrane 
was placed in the top of the receptor compartment and 
checked for air bubbles. An aliquot of the sample was 
measured with the aid of a syringe and then placed in 
the cavity of a dosage wafer (donor compartment), on 
top of the membrane. The amount applied was around 
300 mg of gel, equivalent to 3.48 mg of DDA. With a 
spatula, the gel was spread uniformly filling the donor 
compartment. A glass disk was carefully placed on the 
sample to occlude it, and an aligner cap was then used 
to centralize the assembly, which was held together by a 
clamp. The receptor medium was maintained at 32 ± 1 °C 
under constant stirring. To characterize the drug release, 
400 µL samples were collected after 0.5, 1, 1.5, 2, 3, 4, 
5 and 6 h. In the case of the reference drug product and 
generic A samples were also collected after 0.25 hours. 
After sampling, the volume collected was replaced with 
fresh receptor medium. The amount of DDA was assayed 
by chromatographic analysis as described below.
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DDA assay of release test samples
The DDA assay of the release test samples was 
performed by high performance liquid chromatography 
(HPLC) according to a method previously described in 
the literature (Silva et al., 2009), except that the injection 
volume of 30 µL was reduced to 20 µL. To verify that the 
method is suitable for this purpose the linearity, precision 
and specificity (analyzing the peak purity of the sample 
chromatograms) were evaluated.
Statistical comparison of the in vitro release data
The statistical test used to compare the in vitro 
release rates (fluxes) is a non-parametric statistical 
method, based on a standard confidence interval (CI) 
procedure. This test is related to the Wilcoxon Rank 
Sum/Mann-Whitney rank test, applied to the data for 
the log of the slope (release rate). For the release rate of 
the generic (G) run to be within the 90% CI in relation 
to the reference (R) test run, the values for the G/R ratio 
should lie within the limits of 75% - 133% (FDA, 1997; 
Shah et al., 2003).
Assay of products
The quantitative determination of DDA in the drug 
products was performed by HPLC using the method 
described in the British Pharmacopoeia (2008).
RESULTS AND DISCUSSION
The in vitro drug release profiles for the release 
of DDA from the products, using a polyethersulfone 
membrane, are summarized in Figure 1.
The values for the relative standard deviation 
(RSD) of the in vitro release from the six cells in each 
experiment were less than 10% for all time intervals, 
indicating the good precision of the method. The 
correlation coefficient (r) of 0.9996 obtained from the 
linear regression of the data verified that the method is 
linear in the concentration range investigated in this study 
(10 - 300 µg.mL-1 of sodium diclofenac). The statistical 
calculation of similarity between the chromatogram 
peaks of the standard and the samples resulted in a 
minimum of 99.2% purity. These results showed that the 
excipients do not coeluted with the drug, confirming the 
specificity of the method.
All of the products had satisfactory contents, in 
accordance with the limits set by the British Pharmacopoeia 
of 95-105%.
FIGURE 1 - In vitro release of DDA using a polyethersulfone 
membrane (n=6). Error bars represent the standard deviation 
(SD).
Calculation of the release rate (flux)
Guy and Hadgraft (1990), based on a study published 
by Higuchi (1962), proposed that the processing of data 
obtained from in vitro release studies should include the 
adoption of a function based on the square root of time 
(Figure 2). According to the authors, this procedure is 
necessary for the linearization of the data and the use of 
more points on the profile (Higuchi, 1962; Guy, Hadgraft, 
1990; Bemvindo, 2006). The representation of the amount 
released per unit area (µg/cm2) as a function of the square 
root of time allows the drug release rate for a semisolid 
product to be obtained from the straight line slope (FDA, 
1997; Toscano et al., 2001; Ueda et al., 2009).
According to Higuchi (1962), there is a linear 
relationship between the amount of drug released/diffused 
and √–t when the diffusion through this semisolid matrix is 
the limiting step of the process and in these circumstances 
no other parameter (e.g. receptor medium, membrane) has 
a significant effect.
Also, this relationship has proved to be valid and 
linear for topical formulations where the percentage 
of drug released is less than approximately 30% of the 
amount applied in the donor compartment, forming the 
matrix, for an infinite drug dosage. Thus, the diffusion 
coefficient is not concentration-dependent (Higuchi, 1962; 
Guy, Hadgraft, 1990; Toscano et al., 1997; Shah, 2005).
Additionally, the concentration in the receptor 
compartment should not reach > 10% of the concentration 
limit of solubility of the drug used in the receptor phase 
(Toscano et al., 1997). In the case of DDA, reports in the 
literature indicate that it is very soluble in phosphate buffer 
pH 7.4, with solubility greater than 6.0 mg.mL-1 (Silva 
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et al., 2009). The highest concentration in the receptor 
medium reached in this study did not exceed 0.3 mg.mL-1, 
maintaining sink conditions during the analysis.
Selection of data points to calculate the release 
rate
Zatz and Segers (1998) discuss the selection of data 
points to calculate the in vitro release rate, and state that 
there is a time window during which the experiments 
should be performed. Data should be collected when the 
influence of the membrane and its associated stagnant 
layer are no longer present but before excessive drug 
depletion from semisolid occurs.
On this basis, the DDA flux was calculated by linear 
regression and corresponds to the slope of the first five data 
points obtained a between 0.5 to 3 h. It is assumed that by 
0.5 h the diffusion equilibrium would have been reached 
and after 3 hours the percentage of drug released will not 
characterize a dose depletion sufficient to influence the 
release rate, which was confirmed by the linearity of the 
straight lines.
For the generic A sample the flux was calculated 
from 0.25 to 2 h and the reference flux was calculated from 
0.5 to 3 h and 0.25 to 2 h. The reason for this difference 
in sampling times is that when performing the initial tests 
the sampling points were designed based on the reference 
drug product as the parameter, which released around 
48% of the initial drug content of the semisolid within 3 
hours (Table I) and the straight line formed by the amount 
released as a function of square root of time showed good 
linearity (r = 0.9995).
The release observed for the generic A sample was 
much faster than in the case of the other generic samples. 
Within 3 h, generic A had already released 75% of the drug 
(Table I), forming an undesired curve with values higher 
than the square root of time (Figure 2), as previously 
shown by Zatz and Segers, caused by excessive depletion 
of DDA in the sample. According to the authors, this is to 
be expected when the release exceeds approximately 35-
45% of the initial drug content of the semisolid. At this 
point the basic assumption of the equation that supports 
the linear relationship between the amount of drug released 
and the square root of time is no longer valid.
Thus, for generic A, it is necessary to include another 
sampling point at the beginning of the experiment and 
neglect the data obtained at 3 h. To compare this product 
with the reference using the same points, both samples 
were reanalyzed and subsequently compared with the 
0.25 h sampling point data.
A good linearity for the selected points (Figure 3) 
FIGURE 2 - In vitro release of DDA as a function of √–t, using 
all points, employing the polyethersulfone membrane (n=6).
TABLE I - Percentage of initial DDA content released from the semisolid as a function of time using a polyethersulfone membrane
Time 
(hours)
Time 
(√–hours)
% Released*
Reference Generic A Generic B Generic C Generic D
0.25 0.5 8.76 20.65 -- -- --
0.5 0.7 14.14 31.67 14.61 10.23 7.56
1.0 1.0 23.58 47.37 23.79 17.23 12.56
1.5 1.2 30.93 58.13 31.67 22.02 16.44
2 1.4 38.38 66.05 38.81 27.30 19.33
3 1.7 48.95 75.19 50.89 35.78 24.53
4 2.0 58.11 81.43 59.71 43.79 29.41
5 2.2 65.00 85.13 66.88 51.76 35.01
6 2.4 69.50 86.80 72.79 58.62 40.86
*Mean (n=6)
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was confirmed by the correlation coefficients (r) shown in 
Table II (all above 0.99), ensuring that the release rate was 
constant within these time intervals, for all samples. Thus, 
the kinetics of Higuchi could, in fact, be applied (linear 
plot of amount released versus √–t ).
The lag time is defined as the time required for a 
system involving the passage of a substance through a 
membrane to reach equilibrium (Aulton. 2005). The lag 
time is calculated by extrapolating the linear regression 
line along the time axis. An intercept of “x” which 
generally corresponds to a small fraction of an hour is a 
normal characteristic in release assays plots (FDA. 1997). 
The values in Table II show that the products had a short 
lag time, that is, the diffusion equilibrium of the process 
was established within a short period of time. Therefore, 
the polyethersulfone membrane did not act as a barrier to 
the DDA diffusion.
TABLE II - Release rate, correlation coefficient and lag time of 
products using a polyethersulfone membrane.
Manufacturer Release rate (µg/cm2/√–h)◊
Correlation 
coefficient (r)
Lag time 
(minutes)
Reference* 674.18 ± 53.53 0.9995 5.53
Reference** 637.57 ± 42.72 0.9981 3.85
Generic A** 987.52 ± 25.75 0.9990 0.34
Generic B* 700.27 ± 32.52 0.9990 6.01
Generic C* 489.49 ± 12.76 0.9988 5.74
Generic D* 325.76 ± 13.37 0.9998 3.53
◊Mean ± SD (n=6), *Calculated using the data points within 
0.5 to 3 h, **Calculated using the data points within 0.25 to 2 h
FIGURE 3 - In vitro release of DDA as a function of √–t, using the 
data points selected, employing the polyethersulfone membrane 
(n=6).
Comparison of in vitro release rate
The release results can reflect the combined effect 
of several physical and chemical parameters, including 
the solubility, particle size and rheological properties of 
the dosage form. This explains the differences between 
the formulations evidenced in every test performed 
individually and this is considered as a test to be used for 
the “final quality control” (FDA, 1997).
The formulations of the products analyzed in this 
study had different characteristics, with qualitative and 
possibly quantitative differences in the excipients (Table 
III) and method of preparation (unknown).
Only generic B was considered to be similar to the 
reference drug product according to the statistical method 
used (Table IV). Generic B had a similar profile to the 
reference product, and the qualitative composition of 
the formulation was also found to be closest to Cataflam 
Emulgel®, with the same excipients.
Generic C had a slower release rate than the 
reference. The presence of a consistency agent/co-
emulsifying cetostearyl alcohol may have contributed to 
the lower flux.
Generic D was the generic sample with the lowest 
flux. This was the only sample for which the type of 
surfactant employed was not specified (only given as 
a non-ionic emulsifying wax) and no emollient was 
separately mentioned.
Generic A presented the fastest release rate and 
different excipients, polyacrylamide being used as the 
gel forming polymer rather than Carbopol®, which was 
the excipient in the other samples. The emulsifier (lanolin 
alcohol) also differed from that used in the other samples 
tested and this was the only product that did not contain 
isopropyl alcohol as a solubilizer. This may lead to a 
lower solubility of the vehicle, as the thermodynamic 
activity of the DDA may be higher, thus increasing the 
partition coefficient obtained in the receptor medium. 
These qualitative differences may have facilitated the 
DDA diffusion.
Bemvindo (2006) studied miconazole nitrate 
cream formulations available on the Brazilian market 
and also noted differences in the drug release of the 
products according to the qualitative differences of the 
formulations. Bemvindo reported that the excipient 
propylene glycol present in some formulations increased 
the solubility of miconazole, affecting the thermodynamic 
activity and decreasing the drug partition coefficient of the 
receptor medium.
The in vitro release test alone is not a substitute 
for the assessment of the bioavailability or in vivo 
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bioequivalence of dermatologic formulations produced 
by different manufacturers (FDA, 1997). This is because 
a greater amount of drug release from the formulation 
in in vitro experiments is not a guarantee of increased 
availability of the drug at the site of action, since the 
skin penetration of drugs involves many factors. The 
penetration characteristics of each formulation (e.g. the 
presence of permeation enhancers) will control the amount 
of drug present in each layer of skin (Bemvindo, 2006).
Many different absorption promoters are used for 
various reasons in topical and transdermal preparations. 
For example, a topical formulation may contain propylene 
glycol as the vehicle, a surfactant to solubilize the drug and 
a terpene as a perfume. These formulations can penetrate 
skin to a greater degree due to the presence of these agents, 
although they are not used specifically for this purpose 
(Williams, Barry, 2004).
Although the release test results are only indicative 
of the formulation performance, the flux values obtained 
in these tests allow the following conclusions to be 
drawn: the vehicle used in the generic A sample enabled 
greater release of DDA to the receptor medium used, 
when compared to the reference drug product. If the same 
behavior occurs in vivo, it can be deduced that a higher 
TABLE III - Comparison of diclofenac diethylamine gel formulations
Ingredients 
(Provided on manufacturer’s label)
Function Cataflam Emulgel
®
(Reference) Generic A Generic B Generic C Generic D
Gel-forming 
polymer Carbopol
® Polyacrylamide Carbopol® 934 Carbopol® 940 Carbopol®
Emulsifier Cetomacrogol 1000* Lanolin alcohol Polyoxyl cetostearyl ether
Polyoxyl 20 
cetostearyl ether
Non-ionic 
emulsifying wax
Solvent Isopropyl alcohol - Isopropyl alcohol Isopropyl alcohol Isopropyl alcohol
Humectant Propylene glycol Propylene glycol Propylene glycol Propylene glycol  Propylene glycol
Lipophilic vehicle/ 
Emollient
Liquid paraffin◊,
Coco-caprylate/ 
caprate
Isoparaffin,
Mineral oil◊,
Lauryl alcohol
Liquid petrolatum◊,
Decyl oleate Liquid vaseline
◊ -
Viscosity-increasing 
agent /Co-emulsifier
- - - Cetostearyl alcohol -
Preservative -
Methyl, Propyl,
Butyl and Ethyl 
paraben,
2-phenoxyethanol
- Methyl andPropyl paraben
Methyl and
Propyl paraben
Alkalizing agent Diethylamine - Diethylamine Sodium Hydroxide Sodium Hydroxide
Other Perfume EDTA BHT, Melody essence Fragrance Pentalys essence
* Cetomacrogol 1000 is the commercial name for the polyoxyl cetostearyl ether, ◊ Synonyms
Note: Water and DDA are not present in the table but are constituents mentioned by all manufacturers.
TABLE IV - Statistical testing of difference between reference and generic samples (data collected using polyethersulfone membrane) 
Comparison Limit values of the 90% 
confidence interval
Conclusion*
Reference x Generic A 146.60 - 165.94 NOT SIMILAR
Reference x Generic B 94.99 - 111.93 SIMILAR
Reference x Generic C 66.82 - 77.74 NOT SIMILAR
Reference x Generic D 45.17 - 52.14 NOT SIMILAR
*Requirement for similarity: values must be between 75% and 133.33% (FDA, 1997)
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TABLE V - Release rate, correlation coefficient and lag time of products using a cellulose acetate membrane.
Manufacturer Release rate (µg/cm2/√–h)◊ Correlation coefficient (r) Lag time (minutes)
Reference* 731.63 ± 35.91 0.9992 6.26
Reference** 682.28 ± 34.37 0.9986 4.25
Generic A** 1.032.33 ± 48.76 0.9988 0.67
Generic B* 676.82 ± 7.85 0.9995 5.63
Generic C* 478.50 ± 24.44 0.9993 5.14
Generic D* 326.33 ± 9.32 0.9997 4.16
◊Mean ± SD (n=6). *Calculated using the data points within 0.5 to 3 h; **Calculated using the data points within 0.25 to 2 h
TABLE VI - Statistical test: polyethersulfone membrane x 
cellulose acetate membrane
Polyethersulfone 
membrane x Cellulose 
acetate membrane
p value Conclusion*
Reference 0.1200 SIMILAR
Generic A 0.0569 SIMILAR
Generic B 0.1893 SIMILAR
Generic C 0.2099 SIMILAR
Generic D 0.9108 SIMILAR
*(p < 0.05)
FIGURE 4 - In vitro release of DDA as a function of √–t, using 
the selected data points (data collected employing a cellulose 
acetate membrane and n=6).
amount of DDA will be available to penetrate the skin 
within a shorter time. For the generic C and D samples, 
the DDA probably had greater affinity for the vehicle 
resulting in a lower amount being released in comparison 
with the reference.
This  may affect  the performance of  these 
samples because when drugs are applied topically a 
pharmacologically active agent must be released from its 
vehicle before it can come into contact with the epidermal 
surface and be available for skin penetration (Guy, 1986).
Comparison of the results obtained with 
polyethersulfone and cellulose acetate 
membranes
The in vitro drug release profiles for the DDA 
release from the products tested, using a cellulose acetate 
membrane, are given in Figure 4. The good linearity 
observed for the selected data points was confirmed by 
the correlation coefficients (r) shown in Table V (all above 
0.99), verifying that the release rate was constant during 
the whole test period, for all samples. To statistically 
analyze the flux values obtained with the membranes the 
paired t-test was performed. As can be seen in Table VI, no 
differences were observed between the cellulose acetate 
and polyethersulfone membranes in terms of the flux values 
obtained for the five products (significance level of 5%).
One of the most critical steps in the development of 
an in vitro release method is the selection of the synthetic 
membrane, which must provide an inert support for the 
formulation (Corbo et al., 1993). According to published 
data (Shah et al., 1989; Shah, Elkins, 1995; Shah, Elkins, 
Williamns et al., 1999; Ng et al., 2010) there is no standard 
for the membrane, which should thus be tested for each 
drug, vehicle and receptor medium. The most common 
membranes employed in in vitro release test are silicone, 
cellulose and polysulfone membranes (Ng et al., 2010).
The cellulose acetate and polyethersulfone 
membranes used in this study were both hydrophilic and 
showed similar fluxes, porosity and thickness. DDA, 
an amphiphilic drug (Kriwet, Mueller-Goyman, 1995; 
Djordjevic, Primorac, Stupar, 2005), is compatible with 
hydrophilic membranes. A similar result obtained in a 
comparison between cellulose acetate and polysulfone 
membranes was reported by Bemvindo (2006), where the 
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author found no difference between the two membranes 
in tests with miconazole nitrate cream.
These studies are important for characterizing the 
performance of each drug class according to the release 
test specificities, such as the selection of the membrane.
CONCLUSIONS
The results reported herein indicate that the drug 
release rates for the drug products analyzed were not 
influenced by the type of synthetic membrane used 
(polyethersulfone or cellulose acetate).
Only the generic B sample was considered to be 
similar to the reference drug product, for which the 
formulation was qualitatively most similar to the reference. 
The difference between the fluxes of the products may 
be attributed to different vehicle components. Thus, 
different formulations may result in distinct amounts 
of drug penetration into the skin and may, thus, exhibit 
different intensities of activity (Shah et al., 1991). This 
results obtained highlight the influence of excipients on 
the performance of topical products. However, in vitro 
release tests only provide an indication of the formulation 
performance.
The requirement of the use of this tool, if imposed in 
the future by Brazilian legislation to ensure the equivalence 
of semisolid dosage forms, should be accompanied by 
more stringent criteria regarding the qualitative and 
quantitative excipient composition of generic candidates.
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